Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial
Status:
Completed
Trial end date:
2015-03-04
Target enrollment:
Participant gender:
Summary
This was an open label, randomized study comparing the efficacy and safety of randomized 2:1
Ruxolitinib tablets versus best-available therapy, as selected by the investigator. The
purpose was to compare the efficacy, safety and tolerability of Ruxolitinib
(INC424/INCB018424) given twice daily to the best-available therapy, in subjects with primary
myelofibrosis (PMF), post polycythemia vera myelofibrosis (PPV-MF) or post essential
thrombocythemia myelofibrosis (PET-MF).